Section of Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Urology. 2010 Oct;76(4):857-61. doi: 10.1016/j.urology.2010.04.024. Epub 2010 Jun 19.
To report the first series of laparoendoscopic single-site surgery for radical cystectomy and bilateral pelvic lymph node dissection. The development of laparoendoscopic single-site surgery and its application to urothelial malignancy has not been previously evaluated.
A novel, single multichannel port and flexible laparoscopic instruments and laparoscope were used for all procedures. The eligible patients had transitional cell carcinoma that was muscle invasive or refractory to intravesical therapy. Locally advanced disease, previous abdominal or pelvic surgery or radiotherapy, or those desiring orthotopic reconstruction were excluded. No additional ports were needed, and lymphadenectomy was performed using an extended template up to the aortic bifurcation.
A total of 3 patients (2 men and 1 woman) underwent radical cystectomy with bilateral pelvic lymph node dissection. All the procedures were completed successfully. All patients underwent extracorporeal urinary diversion by way of extension of the umbilical port site. The operative time was 315 ± 40 minutes, and the blood loss was minimal (217 ± 29 mL). The pathologic evaluation revealed negative margins and negative lymph node involvement (mean number of nodes 16 ± 3). All patients were discharged within 1 week (6 ± 1 days) with minimal postoperative pain according to the visual analog pain scale (0-1 of 10). At a minimum of 2 years of follow-up (range 24-26 months), no evidence of recurrent or metastatic disease was detected.
Laparoendoscopic single-site surgery for radical cystectomy and bilateral pelvic lymph node dissection is feasible and safe for select patients. Adequate lymph node dissection was possible through a single multichannel port. The long-term oncologic evaluation of these patients awaits; however, the preliminary outcomes have been promising.
报告首例腹腔镜单部位根治性膀胱切除术和双侧盆腔淋巴结清扫术。腹腔镜单部位手术的发展及其在尿路上皮恶性肿瘤中的应用尚未得到评估。
所有手术均使用新型单多通道端口和灵活的腹腔镜器械和腹腔镜。合格的患者患有肌层浸润性或对膀胱内治疗有抵抗的移行细胞癌。排除局部晚期疾病、既往腹部或盆腔手术或放疗、或希望进行原位重建的患者。无需额外的端口,并且使用扩展模板进行淋巴结清扫术,直至主动脉分叉处。
共有 3 名患者(2 名男性和 1 名女性)接受了根治性膀胱切除术和双侧盆腔淋巴结清扫术。所有手术均成功完成。所有患者均通过脐部端口延长进行体外尿路转流。手术时间为 315±40 分钟,出血量极少(217±29 毫升)。病理评估显示切缘阴性且无淋巴结受累(平均淋巴结数 16±3 个)。所有患者均在 1 周内出院(6±1 天),根据视觉模拟疼痛量表(0-10 分),术后疼痛轻微。在至少 2 年的随访期内(24-26 个月),未发现复发或转移疾病的证据。
腹腔镜单部位根治性膀胱切除术和双侧盆腔淋巴结清扫术对于选择的患者是可行且安全的。通过单多通道端口可以进行充分的淋巴结清扫。这些患者的长期肿瘤学评估仍在等待中;然而,初步结果令人鼓舞。